- Mbappe says victim of 'fake news' after 'rape' report in Sweden
- Russia could be able to attack NATO by 2030: German intelligence
- EVs seek to regain sales momentum at Paris Motor Show
- Clarke backs Scotland to bounce back from 'tough' run
- Harris, Trump target crucial Pennsylvania as US vote looms
- NASA probe Europa Clipper lifts off for Jupiter's icy moon
- Lebanese Red Cross says 18 killed in strike in north
- Mendy borrowed money from Man City team-mates for legal fees
- Palestinian officials say Israeli forces kill two in West Bank
- Football leagues, unions file EU complaint against FIFA in calendar dispute
- Nigeria boycott AFCON qualifier in Libya after 'inhumane treatment'
- India to recall top envoy to Canada: foreign ministry
- Hezbollah, Israeli troops in 'violent clashes' after drone strike
- China insists won't renounce 'use of force' to take Taiwan as drills end
- Painkiller sale plan to US gives France major headache
- Italy begins landmark migrant transfers to Albania
- 'Unsustainable' housing crisis bedevils Spain's socialist govt
- New Zealand 4-0 up in America's Cup but British show signs of life
- Afghan Taliban vow to implement media ban on images of living things
- Russian prosecutor demands 3 years, 3 months jail for French researcher
- England ready for Pakistan's spin assault in second Test
- New Zealand's Ravindra excited for India Tests with father in crowd
- India's capital bans fireworks to curb air pollution
- FIFA to open 'global dialogue' on transfer system after Diarra ruling
- Trio wins economics Nobel for work on wealth inequality
- Starmer vows to cut red tape as he urges foreign investors to 'back' UK
- 'Not viable': Barcelona turns against surging tourism
- Hezbollah says targeted Israeli naval base after deadly drone strike
- Rice praises 'unbelievable' England interim boss Carsley despite uncertainty
- Nepali teenager hailed as hero after climbing world's 8,000m peaks
- England captain Stokes back from injury for second Pakistan Test
- Pakistan 'vigilantes' behind rise in online blasphemy cases
- Nearly 90, but opera legend Kabaivanska is still calling tune
- Smith experiment as Test opener over, Green out of India series
- With inflation down, ECB eyes faster tempo of rate cuts
- Is life possible on a Jupiter moon? NASA goes to investigate
- Dodgers crush Mets 9-0 in MLB playoff series opener
- South Korea military says 'fully ready' as drone tensions soar
- Cummins back, Marsh and Head out of Pakistan ODI series
- Shanghai stocks swing after stimulus briefing as most of Asia rises
- New Zealand's Latham promises 'no fear' as he takes charge for India Tests
- Kyrgios vows to 'shut up' doubters with December comeback
- Public hearings start into death of Brit by Russian nerve agent
- Ex-Stasi officer faces verdict over 1974 Berlin border killing
- Role of government, poverty research tipped for economics Nobel
- 'Stolen satire' feeds US election misinformation
- Rookie McCarty captures first PGA Tour title in Black Desert Championship
- Australia all-rounder Green ruled out of India Test series
- Seeing double in Nigeria's 'twins capital of the world'
- UK FM to attend EU foreign affairs talks for first time in 2 years
Painkiller sale plan to US gives France major headache
The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.
Even President Emmanuel Macron is involved in the debate centred on a perceived "loss of sovereignty" if popular painkiller Doliprane falls into American hands.
Doliprane is the brand under which healthcare giant Sanofi sells paracetamol, a non-opioid analgesic for the alleviation of mild to moderate pain, and of fever.
In French pharmacies, the brand's colourful boxes often line entire shelf walls, and Doliprane comes in many doses -- from 100 mg for newborn babies to 1,000 mg for adults -- and in tablet, capsule, suppository and liquid forms.
It is so ubiquitous that French people call any paracetamol product Doliprane, even when it is made by a different manufacturer.
Sanofi, which is France's biggest healthcare company and among the world's top 12, has found out over the past few days just how attached the French are to the drug.
Political and trade union reactions came in hard and fast after the company announced last week that it was in talks with New York-based private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50-percent controlling stake in its subsidiary Opella, which makes Doliprane along with other consumer healthcare products.
The planned spinoff, it said, would be part of Sanofi's strategy to focus less on over-the-counter medication and more on innovative medicines and vaccines, including for polio, the flu and meningitis.
"This is another symbol for the loss of our sovereignty," thundered Fabien Roussel, France's Communist party leader, calling the planned sale "shameful".
At the other end of the political spectrum Jordan Bardella, president of the farright RN party, said that "the piecemeal sale of France carries on".
- 'Protect France' -
Green party deputy Marine Tondelier said the government had "learned nothing" from the Covid pandemic when France suffered from medication bottlenecks blamed mostly on the outsourcing of production to foreign countries.
An adhoc group of centre-right lawmakers -- including from Macron's party -- meanwhile stated that the sale represented "a very worrying risk for our national security".
Boris Vallaud, parliamentary leader for the Socialists, reminded the government of 2022 when a sharp rise in demand for paracetamol caused some shortages in French pharmacies.
"Already some months ago, paracetamol was nowhere to be found," he said. "And now they want to give it up completely?"
In a message to Finance Minister Antoine Armand -- in the job only since last month -- the group of deputies said the planned sale went against "the re-establishment of France's sovereignty in the health sector".
The government had the legal option, they said, of posing conditions or blocking the sale on the grounds that it concerns a "sensitive" industry.
Macron himself entered the fray Monday, saying that "the government has the instruments needed to protect France" from any unwanted "capital ownership".
The American investment fund is offering more than 15 billion euros ($16.4 billion) for Opella, according to Les Echos, a French business daily.
Faced with the protests, Armand on Friday told Sanofi and the potential buyer that Opella's "headquarters and decision-making centres" had to remain in France.
On Monday, Industry Minister Marc Ferracci said that current production also had to stay, "to safeguard employment and to secure supply for French people".
The same went for research and development facilities, he said.
Speaking to broadcaster France 3, Ferracci said the government would invoke a procedure for the control of foreign investment if the buyers failed to meet the demands.
But he added: "I honestly believe that those commitments will be made."
burs-jh/as/rl
G.Teles--PC